Jazz Pharmaceuticals Acquires GW Pharmaceuticals for $7.2 billion

Pfizer Acquires Global Blood Therapeutics for $5.4 Billion

August 8, 2022

Biotechnology

Pfizer Inc. has agreed to acquire Global Blood Therapeutics, Inc. for $68.50 per share in cash, valuing the transaction at approximately $5.4 billion including debt. The acquisition brings GBT's sickle cell disease portfolio (including Oxbryta) and pipeline to Pfizer to expand its rare hematology capabilities and accelerate access to therapies for underserved SCD patient communities.

Pfizer Acquires Seagen for $43 Billion

December 14, 2023

Biotechnology

Pfizer completed the acquisition of Seagen, acquiring all outstanding Seagen common stock for $229 per share in cash in a transaction valued at approximately $43 billion. The deal adds Seagen's ADC technology, four in-line oncology medicines and a large early-stage pipeline to Pfizer's oncology portfolio, expanding Pfizer's capabilities and doubling its oncology pipeline.

CNX Therapeutics Acquires Sativex from Jazz Pharmaceuticals

October 31, 2025

Pharmaceuticals

CNX Therapeutics has acquired the global Sativex (nabiximols) business from Jazz Pharmaceuticals, with the deal closing on 31 October 2025. The transaction includes marketing authorisations and commercial rights worldwide and the UK entity SVX Therapeutics Limited; Jazz will support a transition period under a Transition Service Agreement.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Biotechnology

Gilead Sciences has completed the acquisition of CymaBay Therapeutics for approximately $4.3 billion, paying $32.50 per share in cash. The deal adds CymaBay's investigational PPARδ agonist seladelpar for primary biliary cholangitis (PBC) to Gilead's liver-disease portfolio and is expected to accelerate development and potential commercialization of the therapy.

UCB to Acquire Zogenix for up to $1.9B

January 19, 2022

Pharmaceuticals

UCB (Euronext: UCB) has agreed to acquire Zogenix, Inc. (NASDAQ: ZGNX) in a cash tender offer valuing the deal at up to approximately US$1.9 billion, consisting of US$26.00 per share in cash plus a contingent value right of up to US$2.00 per share tied to regulatory milestones. The acquisition adds Zogenix's FINTEPLA (fenfluramine) — an approved treatment for seizures associated with Dravet syndrome and under review for Lennox-Gastaut syndrome — to UCB's neurology and rare disease portfolio and is expected to expand UCB's epilepsy pipeline and global commercial reach.

GlaxoSmithKline Acquires Sierra Oncology for $1.9bn

April 13, 2022

Biotechnology

GlaxoSmithKline plc (GSK) has agreed to acquire late-stage biopharmaceutical company Sierra Oncology for $55 per share in cash, representing an approximate equity value of $1.9 billion. The acquisition, expected to close in Q3 2022 subject to customary approvals, brings momelotinib — a late-stage JAK/ACVR1 inhibitor with demonstrated benefit on symptoms, splenic response and anaemia in myelofibrosis — into GSK's haematology portfolio to strengthen its specialty medicines capability and global commercial reach.